五洲医疗(301234) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was CNY 147,385,573.73, representing a 4.08% increase year-over-year, while the year-to-date revenue reached CNY 396,005,110.69, up 8.76% compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2022 was CNY 17,472,933.29, a decrease of 27.29% year-over-year, and the year-to-date net profit was CNY 48,947,073.37, down 5.83% compared to the previous year[5] - The basic earnings per share for Q3 2022 was CNY 0.2570, reflecting a decline of 45.47% year-over-year, while the diluted earnings per share also stood at CNY 0.2570[5] - The weighted average return on equity was 2.80%, down 6.14% year-over-year, indicating a decline in profitability[5] - The total comprehensive income for the period was ¥48,947,073.37, consistent with the net profit, indicating no other comprehensive income adjustments[22] Assets and Liabilities - The total assets as of September 30, 2022, were CNY 832,251,174.63, an increase of 117.26% from the end of the previous year, and the equity attributable to shareholders was CNY 701,459,956.13, up 166.95%[5] - The company reported a total current liability of CNY 122,534,923.67, compared to CNY 110,781,640.05 at the beginning of the year[19] - Total liabilities increased to ¥130,791,218.50 from ¥120,297,328.32, marking an increase of 4.1%[22] Cash Flow - The net cash flow from operating activities for the year-to-date period was CNY 81,263,629.63, showing a significant increase of 53.25% compared to the same period last year[11] - The net cash flow from financing activities reached CNY 397,351,664.55, a dramatic increase of 3,055.84% due to the proceeds from the initial public offering of shares[11] - The company experienced a 222.43% increase in net cash flow from investing activities, amounting to CNY -115,800,794.90, primarily due to the implementation of fundraising investment projects[11] - The net cash flow from operating activities for Q3 2022 was ¥81,263,629.63, an increase of 53.1% compared to ¥53,026,553.40 in Q3 2021[24] - The total cash inflow from operating activities amounted to ¥456,927,319.61, up from ¥407,063,589.97 in the same period last year, reflecting a growth of 12.2%[24] - The net cash flow from financing activities reached ¥397,351,664.55, a substantial improvement from a negative cash flow of -¥13,442,957.46 in Q3 2021[24] Shareholder Information - Total number of common shareholders at the end of the reporting period is 13,847[13] - The top shareholder, Huang Fan, holds 24.16% of shares, totaling 16,429,650 shares[13] - The company issued 17 million shares in its initial public offering, increasing total shares from 51 million to 68 million[15] - The company has a total of 1,700 million shares issued in its IPO, which was approved by the China Securities Regulatory Commission on May 17, 2022[15] Expenses - The company reported a significant increase in management expenses, which rose by 66.89% to CNY 14,205,801.86, primarily due to costs associated with the company's stock market listing activities[10] - Research and development expenses were ¥9,492,628.04, an increase of 17.6% compared to ¥8,080,580.28 in the previous period[21] - The cash outflow for employee compensation was ¥49,243,776.54, up from ¥43,316,444.53 in Q3 2021, reflecting a 13.5% increase[24] Government Support - The company reported a total of CNY 9,566,496.18 in government subsidies recognized during the year, contributing positively to its financial performance[7] Cash and Cash Equivalents - Cash and cash equivalents increased to CNY 413,567,937.77 from CNY 43,329,298.72 at the beginning of the year[18] - The total cash and cash equivalents at the end of Q3 2022 were ¥407,725,283.88, compared to ¥50,638,299.14 at the end of Q3 2021, marking a significant increase[24] - The impact of exchange rate changes on cash and cash equivalents was a positive ¥3,506,012.82, contrasting with a negative impact of -¥22,708.52 in the previous year[24]